Your browser doesn't support javascript.
loading
Trends in hematopoietic stem cell transplant activity in Lebanon.
Bazarbachi, Ali; Zahreddine, Ammar; Massoud, Radwan; El Cheikh, Jean; Hanna, Colette; Nasr, Fadi; Abboud, Miguel; Ibrahim, Ahmad.
Affiliation
  • Bazarbachi A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: bazarbach@aub.edu.lb.
  • Zahreddine A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Nursing Services, American University of Beirut Medical Center, Beirut, Lebanon.
  • Massoud R; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • El Cheikh J; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Hanna C; Division of Hematology and Oncology, Mount Lebanon Hospital, Baabda, Lebanon.
  • Nasr F; Division of Hematology and Oncology, Mount Lebanon Hospital, Baabda, Lebanon.
  • Abboud M; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, American University of Beirut, Beirut, Lebanon.
  • Ibrahim A; Department of Internal Medicine, Division of Hematology and Oncology, Makassed General Hospital, Beirut, Lebanon.
Hematol Oncol Stem Cell Ther ; 10(4): 315-320, 2017 Dec.
Article in En | MEDLINE | ID: mdl-28641098
ABSTRACT
Hematopoietic stem cell transplantation (HSCT) has been accessible to the population residing in Lebanon and surrounding countries since 1997. HSCT programs were developed in two major hospitals in Beirut American University of Beirut Medical Center (AUBMC) and Makassed General Hospital. Mount Lebanon Hospital initiated an autologous HSCT activity later. Between 2012 and 2016, the HSCT activity in Lebanon reached a total of 897 transplants, among which 303 (33.8%) were allogeneic HSCT and 594 (66.2%) were autologous HSCT. Overall, autologous HSCT activity has remained stable over the past 5years, whereas allogeneic HSCT activity has seen a steep increase between 2012 and 2013 followed by a modest increase later. Haploidentical transplantation has mushroomed and represented almost half of allogeneic HSCT activity in 2016. AUBMC and Makassed General Hospital are members of the European Blood and Marrow Transplantation (EBMT) and East Mediterranean Blood and Marrow Transplantation groups, and AUBMC has been accredited by JACIE (Joint Accreditation Committee - ISCT & EBMT) since 2016. The past 5years have seen an increase in HSCT-related research and publications, mainly from AUBMC. These research activities were predominantly focused on personalized conditioning for allogeneic HSCT and post-transplant maintenance therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms / Immunologic Deficiency Syndromes / Metabolism, Inborn Errors Type of study: Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Asia Language: En Journal: Hematol Oncol Stem Cell Ther Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms / Immunologic Deficiency Syndromes / Metabolism, Inborn Errors Type of study: Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Asia Language: En Journal: Hematol Oncol Stem Cell Ther Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2017 Document type: Article